TIS 0.00% 0.0¢ tissue therapies limited

rbs morgans say buy, page-3

  1. 2,211 Posts.
    lightbulb Created with Sketch. 74
    This is an extract from the RBS Morgans research giving the milestone planned timeline and their relative thoughts of their effectiveness if achieved.

    This information will be available from the TIS web site but just encapsulates it well.

    Regards...........

    Table 1 : Milestone table
    Expected date Milestone Expected catalyst
    Jul-11 Interim results EU multicentre venous ulcer trial ? full results
    in Sept
    Positive
    3QCY11 (was 2QCY11) Formal FDA request for designation as a device Positive
    4QCY11 Regulatory approval for sale: starting for Rest of World Positive
    1QCY12 Approval for sale in EU Very Positive
    2QCY12 Sales launch in EU Very Positive
    3QCY12 Venous ulcer clinical trial completed in US Positive
    3QCY12 World-wide launch outside EU and US: starting for Rest
    of World
    Positive
    2QCY13 Approval VitroGro? for treatment of venous ulcers Very Positive
    3QCY13 US launch of VitroGro? for treatment of venous ulcers Very Positive
    2QCY13 Diabetic and pressure ulcer clinical trials completed in US Positive
    4QCY13 Approval of VitroGro? for treatment of diabetic and pressure


    ulcers in US
    Very Positive
    1QCY14 US launch of VitroGro? for treatment of diabetic and pressure
    ulcers
    Positive
    Source: Company data, RBS Morgans forecasts
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.